Is a
Patent attributes
Patent Jurisdiction
Patent Number
Date of Patent
August 23, 2016
Patent Application Number
13768005
Date Filed
February 15, 2013
Patent Citations Received
Patent Primary Examiner
Patent abstract
Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
